Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

46.86 -0.08 (-0.17%)
Official Closing Price Updated: 7:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
42 43 Next >
GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
GSK and CureVac restructured their collaboration into a new licensing agreement, prioritizing mRNA vaccine development. GSK gains full control of vaccine candidates for influenza and COVID-19, while... 
Via Benzinga
3 No-Brainer Stocks to Buy With $300 Right Now for the Second Half of 2024
A modest amount of money can go a long way when it's put to work in highly innovative, game-changing businesses. 
Via The Motley Fool
Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims
A Delaware judge dismissed GSK and other drugmakers' appeal, allowing over 70,000 lawsuits alleging Zantac causes cancer to proceed, with the companies needing Delaware Supreme Court approval to... 
Via Benzinga
Topics Lawsuit
CDC Advisor Panel Recommends RSV Shots In US For People Above 75 Years, Analyst Says Decision Negative For GSK
The CDC's ACIP recommends RSV vaccines for adults 75+, and for those 60-74 with chronic conditions. GSK's Arexvy is approved for adults 50-59 at risk. A decision on adults 50-59 is pending further... 
Via Benzinga
Why Is Moderna Stock Trading Lower On Wednesday?
The CDC's Advisory Committee on Immunization Practices is set to discuss recommendations for RSV, influenza, and COVID-19 vaccines. Moderna's data shows vaccine efficacy drops to 50% after 18 months in... 
Via Benzinga
Moderna Crumbles After RSV Vaccine Effectiveness Pales Vs. Pfizer, GSK Shots
After 18 months, Moderna's RSV vaccine proved about 50% effective against lower respiratory tract disease. 
Via Investor's Business Daily
Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC
Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners. 
Via Benzinga
UK Chooses Pfizer Over GSK for Multi-Million Dose RSV Vaccine Contract
Pfizer secures a UK contract to supply millions of doses of its Abrysvo RSV vaccine, surpassing GSK's bid. The agreement includes doses for older adults and pregnant mothers. 
Via Benzinga
Industry Groups Back GSK's Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer
GSK, supported by major industry groups, seeks to stop 70,000 Zantac lawsuits in Delaware, arguing a recent court ruling threatens the state's business-friendly reputation and judicial consistency. 
Via Benzinga
Topics Lawsuit
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GOVX),(NYSE:GSK),(NASDAQ:AZN),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
Discover Cantor Fitzgerald's analysis on Innoviva, highlighting its unique royalty-based business model with GSK for asthma and COPD products. 
Via Benzinga
7 A-Rated Biotech Stocks Worth Betting on in June
A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation. 
Via InvestorPlace
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
From FN Media Group LLC
Via GlobeNewswire
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
Don’t miss out on these three penny stocks, which have amazing potential to take off following upcoming business developments this year. 
Via InvestorPlace
Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK
If approved, this would be the first combination vaccine based on mRNA technology to hit the market. 
Via Investor's Business Daily
US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
From GSK plc
Via Business Wire
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
These undervalued pharma stocks to buy are worth a look because even when the economy is struggling, consumers need key medicines. 
Via InvestorPlace
Topics Economy
Large Cap BIopharmaceuticals Overview
As a defensive play healthcare is weighted at about 12% of the S&P 500. 
Via Talk Markets
Topics Stocks
GSK Stock Falls as 70,000 Zantac Lawsuits Move Forward. What to Know.
Investors in GlaxoSmithKline are seeing a lot of red on their screens today, as GSK stock falls more than 8% on big legal news. 
Via InvestorPlace
Topics Lawsuit
GSK's Blenrep Combo Therapy Cuts Risk Of Disease Progression Or Death By Around 50% In Pretreated Multiple Myeloma
GSK presented interim results from the DREAMM-8 phase 3 trial at ASCO 2024. Blenrep (belantamab mafodotin) with PomDex showed a significant improvement in progression-free survival for relapsed or... 
Via Benzinga
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
 
Via Benzinga
Zantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move Forward
GSK shares fell as the Delaware State Court allowed over 70,000 lawsuits regarding the discontinued heartburn drug Zantac (ranitidine) to proceed. This ruling contradicts a Federal Court's 2022... 
Via Benzinga
Topics Lawsuit
GSK, Boston Beer And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
From GSK plc
Via Business Wire
Is Moderna Stock a Buy Now That It's a 2-Product Company?
The Food and Drug Administration recently approved a new vaccine from Moderna, but the stock dipped in response. 
Via The Motley Fool
Why GameStop Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
From GSK plc
Via Business Wire
Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK
Moderna's RSV vaccine will launch a year behind Pfizer and GSK, but it could become the market leader over the next five years. 
Via Investor's Business Daily
AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report
Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers. 
Via Benzinga
Zantac Verdict: Jury Finds No Link To Colon Cancer In Initial Trial, GSK And Boehringer Prevail In First Zantac Cancer Lawsuit
Chicago jury rejects woman's claim that Zantac caused her colon cancer. First of thousands of similar lawsuits, companies deny scientific evidence. 
Via Benzinga
Topics Lawsuit
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
42 43 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.